WT1 and acute myeloid leukemia: In a stage II clinical trial, DCs electroporated with Wilms’ tumor 1 (WT1) mRNA were reported to be an efficient method for preventing or delaying AML relapse following standard chemotherapy with the production of WT1-specific CD8+ T cell response [84].